Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

August 20, 2019August 22, 2019

ICER Will Compare Lead Candidate Therapies Crizanlizumab and Voxelotor for Efficacy, Value

News

An upcoming analysis by the Institute for Clinical and Economic Review (ICER) will compare the clinical efficacy and economic value of Novartis’ crizanlizumab and Global Blood Therapeutics‘ voxelotor, lead ... Read more

August 13, 2019August 13, 2019

Cognitive Decline Not Evident in Black Americans with Sickle Cell Trait, Study Finds

News

African-Americans with sickle cell trait, carriers for sickle cell but without the disease, have no greater risk of cognitive decline than other adults of similar age, an analysis of a ... Read more

August 8, 2019August 8, 2019

Survival After Kidney Transplant Lower in SCD Patients Than Other Kidney Disease Patients, Analysis Shows

News

Survival of sickle cell disease patients (SCD) with end-stage renal disease who undergo kidney transplant is significantly lower compared to other renal disease patients who have the same procedure, ... Read more

August 6, 2019August 6, 2019

Phase 3 Trial of Rivipansel in Treating SCD Pain Crisis Fails to Meet Goals, Pfizer Announces

News

The Phase 3 RESET trial testing the effectiveness and safety of rivipansel (GMI-1070), Pfizer‘s investigational candidate to treat vaso-occlusive crisis (VOC) in hospitalized patients with sickle cell disease (SCD), failed to reach both ... Read more

July 25, 2019July 25, 2019

T-cells Promote Inflammation in Children with Sickle Cell as well as Adults, Study Finds

News

Children with sickle cell disease, like adults, have a distinct group of immune cells, called innate like T-cells, that appear to promote the chronic inflammation associated with SCD, researchers ... Read more

July 11, 2019July 11, 2019

Non-Invasive Prenatal Screening Test for Sickle Cell Appears Possible, Study Reports

News

A non-invasive prenatal test to diagnose a risk of sickle cell disease in a baby is possible and may be available in clinics in a near future, if further testing ... Read more

June 27, 2019June 27, 2019

Early Treatment with Hydroxyurea Lessened SCD Severity Among Infants, Study Shows

News

Treatment with hydroxyurea since early infancy, starting at the age of one, is effective and safe at preventing sickle cell disease (SCD) complications, a follow-up study has found. The ... Read more

June 25, 2019June 25, 2019

Investigational Oral Inhibitor IMR-687 Shows Promising Results in Ongoing Phase 2 Clinical Trial

News

Imara’s investigational oral inhibitor IMR-687 is well-tolerated, and shows signs of potential for lowering blood biomarkers of sickle cell anemia (SCA), early data from a Phase 2 trial show. ... Read more

May 23, 2019May 23, 2019

Participants Sought for Trial Evaluating Olinciguat for Sickle Cell Disease

News

The Phase 2 STRONG-SCD clinical trial evaluating olinciguat as an investigational therapy for sickle cell disease is seeking participants. Olinciguat, being developed by Cyclerion Therapeutics (a spin-off of Ironwood Pharmaceuticals), ... Read more

May 14, 2019May 14, 2019

Cognitive Function May Be Affected in Adults with Sickle Cell Disease, Study Suggests

News

Adults with sickle cell disease score worse than their healthy, unaffected siblings on cognitive tests, despite treatment with hydroxyurea, a study reports. The study “Neurocognitive functioning in symptomatic adults ... Read more